CW
IBRX icon

CreativeOne Wealth’s ImmunityBio IBRX Stock Holding History

CreativeOne Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.4K Buy
+10,480
New +$71.7K ﹤0.01% 1159

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

CreativeOne Wealth's IBRX Position: Q1 2026 in Review

CreativeOne Wealth opened a new position in ImmunityBio (IBRX) in Q1 2026: 10,480 shares worth $80.4K. The stake represents ﹤0.01% of the portfolio and ranks #1159 among its holdings.

386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • CreativeOne Wealth held 10,480 shares of ImmunityBio worth $80.4K as of Q1 2026.
  • ImmunityBio was a new CreativeOne Wealth position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of CreativeOne Wealth's portfolio in Q1 2026, its #1159 holding.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on CreativeOne Wealth's 13F filing for Q1 2026, filed 15 May 2026.